Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966142 · ClinicalTrials.gov registry record · NA
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 1,048
- Enrollment target
NCT05966142 is a NA study that has completed, run by Duke University. The registered enrollment target is 1,048 participants.
The verdict
NCT05966142, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,048 participants
- Enrollment target
Study Summary
This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial. Participants can enroll in only one of the three trials. All three trials were registered on ClinicalTrials.gov under NCT04445792. In July 2023 each of the three treatment trials was registered under a separate NCT# and NCT04445792 was converted to a screening record per recent guidance on master protocol research programs (MPRPs). This record is specific to the Chronic Pain Trial within the ADOPT-PGx protocol. The Chronic Pain Trial is a prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided opioid therapy (Intervention arm) or standard care with 6-month delayed pharmacogenetic testing (Control arm). The investigators will test the hypothesis that pharmacogenetic testing and genotype guided pain therapy improves pain control after surgery in participants who's body processes some pain medicines slower than normal.
Interventions
- OTHER Pharmacogenetic testing
- OTHER Clinical decisions support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,048 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2024-05-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966142
The ClinicalTrials.gov registry entry for NCT05966142 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,048 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic testing is the first listed.
NCT05966142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05966142 about?
NCT05966142 is a clinical study titled "A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)". This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial. Participants can enroll in only ...
What is the current status of trial NCT05966142?
This trial is currently completed. It is a NA study. The enrollment target is 1,048 participants. The study started on 2021-02-24. Estimated completion is 2024-05-10.
What interventions are being tested in trial NCT05966142?
The interventions under investigation include: Pharmacogenetic testing (OTHER), Clinical decisions support (OTHER).
Who is sponsoring clinical trial NCT05966142?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.